Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.63 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12720825 | 0.92 | AGTR1 (0.66) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL12720823 | 0.90 | AGTR1 (0.88) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL1028452 | 0.88 | AGTR1 (0.91) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL12720811 | 0.88 | AGTR1 (0.58) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL1025581 | 0.85 | AGTR1 (0.76) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL1028098 | 0.84 | AGTR1 (0.74) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL30873792 | 0.84 | RAB9A (0.72) | AGTR1RAB9ASMN1; SMN2NPC1GAA | |
| SCHEMBL12720841 | 0.84 | RAB9A (0.88) | AGTR1RAB9ASMN1; SMN2NPC1GAA | |
| SCHEMBL12955841 | 0.84 | AGTR1 (0.60) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 | |
| SCHEMBL15741850 | 0.83 | AGTR1 (1.00) | AGTR1RAB9ASMN1; SMN2NPC1NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928049-B2 | Use of metal complex compounds as oxidation catalysts | BASF SE Ludwigshafen (DE) | 2011-04-19 | — | — | US | disclosed |
| US-7928049-B2 | Use of metal complex compounds as oxidation catalysts | BASF SE Ludwigshafen (DE) | 2011-04-19 | — | — | US | disclosed |
| US-20110021407-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021407-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009013163-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | BASF SE (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021407-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | SOD1, MPO, LPO | AGTR1 2778/4885RAB9A 4379/4885SMN1; SMN2 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.